Semaglutide for Stroke Prevention

How Semaglutide Helps with Stroke Prevention

Semaglutide mimics the GLP-1 hormone to reduce appetite and slow stomach emptying, leading to significant weight loss. For patients with stroke prevention, this weight loss translates to meaningful improvements in condition-specific outcomes.

GLP-1 medications address multiple stroke risk factors simultaneously through weight loss, blood pressure reduction, improved lipid profiles, and better glycemic control. The STEP clinical trial program demonstrated that semaglutide 2.4mg weekly produces an average weight loss of 15% of body weight over 68 weeks, with additional benefits for metabolic health markers.

Clinical Evidence for Stroke Prevention

Stroke Prevention affects approximately 795,000 strokes occur annually in the US with obesity being a top modifiable risk factor. Research shows that GLP-1 medications like semaglutide address both the weight component and the underlying metabolic dysfunction associated with stroke prevention. Patients with this condition often see compounding benefits from weight loss, including improved energy, mobility, and overall quality of life.

Semaglutide Dosing for Stroke Prevention

Semaglutide is taken as a once-weekly subcutaneous injection. The standard titration starts at 0.25mg and gradually increases to the maintenance dose of 2.4mg over 16-20 weeks. Dosing is the same regardless of the indication — your provider will monitor your response and adjust timing as needed.

Cost of Semaglutide for Stroke Prevention

Compounded semaglutide costs $149-399/month through telehealth providers. Brand-name Wegovy costs $1,300+/month without insurance. Many patients with stroke prevention have associated comorbidities that improve insurance coverage chances.